3 completed, 1 active not recruiting, 1 terminated, 1 unknown. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Generalized Pustular Psoriasis: new trials by email Literature Review of Generalized Pustular Psoriasis trials Research Report on Generalized Pustular Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis TQH2929 Injections, TQH2929 Placebo - Generalized Pustular Psoriasis | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 36 | 2026-03-19 | 2026-08-03 |
| Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis HB0034 - Generalized Pustular Psoriasis | Phase 2 / Phase 3 | Unknown | Shanghai Huaota Biopharmaceutical Co., Ltd. | 33 | 2024-09-02 | 2025-02-14 |
| A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis Spesolimab, Placebo - Generalized Pustular Psoriasis | Phase 2 | Completed | Boehringer Ingelheim | 123 | 2020-06-04 | 2025-10-20 |
| Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study Spesolimab - Generalized Pustular Psoriasis | Phase 2 | Active not recruiting | LEO Pharma | 131 | 2019-05-29 | 2026-09-01 |
| Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis Spesolimab, Placebo - Generalized Pustular Psoriasis | Phase 2 | Completed | Boehringer Ingelheim | 53 | 2019-01-31 | 2025-10-16 |
| A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis Imsidolimab - Generalized Pustular Psoriasis | Phase 2 | Completed | Vanda Pharmaceuticals | 8 | 2019-01-30 | 2025-09-16 |
Psoriasis (6)
Skin Diseases (6) · Skin Diseases, Papulosquamous (6) · Skin and Connective Tissue Diseases (6)
spesolimab (3)
Boehringer Ingelheim (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · LEO Pharma (1) · Shanghai Huaota Biopharmaceutical Co., Ltd. (1) · Vanda Pharmaceuticals (1)
China (5) · South Korea (4) · United States (4) · France (3) · Germany (3) · Japan (3) · Malaysia (3) · Taiwan (3) · Thailand (3) · Tunisia (3) · Argentina (2) · Belgium (2) · Chile (2) · Italy (2) · Mexico (2)
PMID 33785490, PMID 34936739, PMID 36333618, PMID 37840119, PMID 39104539, PMID 40057892
2017 (2), 2018 (2), 2023 (1)